Three patient deaths have been linked to connectivity issues with these devices. The FDA has classified this as a Class I recall. Three patient deaths have been linked to connectivity issues with these devices. The FDA has classified this as a Class I recall. | | |
|
A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen. A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen. | | |
|
ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike. ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike. | | |
|
All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell. All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell. | | |
|
The proposal, first announced by the Biden administration, was developed to improve patient data security. Those opposed argue that it would significantly increase costs and create a logistical nightmare for hospitals and health systems throughout the country. The proposal, first announced by the Biden administration, was developed to improve patient data security. Those opposed argue that it would significantly increase costs and create a logistical nightmare for hospitals and health systems throughout the country. | | |
|
After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. | | |
|
AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities. AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities. | | |
|
The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging. The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging. | | |
|
Kirk Milhoan, MD, PhD, has been fired from his role as a pediatric cardiologist. His wife and others say he was let go because he is now the chair of the CDC’s Advisory Committee on Immunization Practices. Kirk Milhoan, MD, PhD, has been fired from his role as a pediatric cardiologist. His wife and others say he was let go because he is now the chair of the CDC’s Advisory Committee on Immunization Practices. | | |
|
Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026. Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026. | | |
|
The error caused incorrect glucose data to be displayed to clinicians. According to Medtronic, any treatment decisions or recommendations based on those data need to be revisited. The error caused incorrect glucose data to be displayed to clinicians. According to Medtronic, any treatment decisions or recommendations based on those data need to be revisited. | | |
|
